Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Oxyntomodulin
Metabolic & Weight Loss
Molecular Dossier
- Rank Index: 83
- Status: Research Only
- What does this mean?
- Molecular Structure: MW: 4479.1 Da | 37 AA | CAS: 169086-86-6 | Derived from: proglucagon (aa 33-69) | Endogenous dual GLP-1R/GcgR agonist
About Oxyntomodulin
Oxyntomodulin (OXM) is an endogenous 37-amino acid proglucagon-derived peptide released postprandially from intestinal L-cells alongside GLP-1 and PYY. It is a naturally occurring dual agonist at both the GLP-1 receptor (GLP-1R) and glucagon receptor (GcgR) — the same receptor combination targeted by the novel synthetic dual agonists survodutide and pemvidutide, which were purpose-engineered to replicate and enhance OXM's pharmacology. OXM's GLP-1R activity produces satiety, slowed gastric emptying, and enhanced insulin secretion; its GcgR activity drives hepatic glucose output reduction, thermogenesis, and energy expenditure enhancement. In human studies, intravenous and subcutaneous OXM infusions reduce food intake by 19–25% and increase total energy expenditure by approximately 2.5% per dose — effects exceeding either GLP-1 or glucagon alone, supporting the concept of additive or synergistic dual-receptor activity. Long-term OXM studies in obese subjects demonstrate progressive weight loss with preserved lean mass, attributed to the metabolic benefits of glucagon receptor activation that prevent the muscle loss associated with pure caloric restriction. The native peptide has poor drug-like properties: half-life is only ~12 minutes due to DPP-4 cleavage and renal clearance, making it impractical as a pharmaceutical without modification. The synthetic analogues (survodutide, cotadutide, pemvidutide) are essentially long-acting, potency-optimized OXM mimetics. Understanding OXM provides the mechanistic foundation for the entire GLP-1/glucagon dual agonist drug class.
Clinical Focus
GLP-1/Glucagon Dual Agonism — Appetite Suppression & Energy Expenditure
Archival Aliases
OXM, Proglucagon fragment, Gut incretin GLP-1/glucagon dual
Frequently Asked Questions
How does oxyntomodulin compare to synthetic GLP-1/glucagon dual agonists like survodutide?
Oxyntomodulin is the endogenous template that inspired the synthetic dual agonist class, but it is far less potent at both GLP-1R and GcgR than purpose-built synthetic analogues. OXM's GLP-1R affinity is approximately 50-fold lower than GLP-1 itself, and its GcgR affinity is about 10-fold lower than native glucagon. Survodutide and pemvidutide are engineered to have high affinity at both receptors simultaneously, tunable GLP-1R:GcgR ratio, and long half-lives (once-weekly dosing). OXM by contrast requires infusion for sustained effect. The synthetic analogues are essentially pharmacologically optimized OXM mimetics — OXM provides the proof-of-concept mechanism; the synthetics provide the drugability.
Why isn't oxyntomodulin developed as a drug if it causes weight loss in humans?
Several pharmaceutical attempts to develop OXM as a drug have been made, but the molecule's poor drug-like properties present major hurdles: (1) 12-minute half-life requires subcutaneous infusion pumps or multiple daily injections. (2) Rapid DPP-4 cleavage at the His7 position (same as GLP-1) eliminates GLP-1R activity within minutes. (3) The GLP-1R and GcgR activities cannot be independently tuned in the native structure. (4) Manufacturing a 37-amino acid peptide with consistent purity at pharmaceutical scale is more complex than smaller analogues. The industry consensus shifted toward engineering superior synthetic analogues (survodutide, pemvidutide) that retain OXM's dual-agonism concept while solving all its pharmaceutical limitations.
How much does oxyntomodulin increase energy expenditure and why?
In human infusion studies, subcutaneous OXM increased resting energy expenditure (REE) by approximately 2.5% per administration. Over a 4-week period of twice-daily injections in clinical trial subjects, total energy expenditure increased by approximately 140 kcal/day. This is attributed primarily to glucagon receptor-mediated thermogenesis — glucagon activates brown adipose tissue (BAT), increases hepatic fat oxidation, and stimulates UCP-1 expression. The GLP-1R component contributes appetite suppression but not significant direct thermogenesis. This dual effect (eat less + burn more) is the pharmacological rationale for the dual agonist class: GLP-1R monotherapy primarily reduces intake; adding GcgR agonism adds the thermogenic dimension.
What is oxyntomodulin's native half-life and what degrades it?
Native oxyntomodulin has a plasma half-life of approximately 12 minutes in humans. It is degraded by two enzymes: DPP-4 (dipeptidyl peptidase-4), which cleaves the His-Ser N-terminal dipeptide from both GLP-1R and GcgR binding domains, and neprilysin, which cleaves internal peptide bonds. DPP-4-resistant analogues (replacing His1 with Aib or other alpha-methyl amino acids) can extend half-life to hours. The fatty acid conjugation strategy used in semaglutide and tirzepatide's GIP component has been applied to OXM analogues as well, achieving once-weekly half-lives in pharmacokinetic studies. This chemical space — DPP-4-resistant, acylated OXM analogues — is the active area of development for the next generation of dual agonists.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | MW: 4479.1 Da | 37 AA | CAS: 169086-86-6 | Derived from: proglucagon (aa 33-69) | Endogenous dual GLP-1R/GcgR agonist |
| Primary Pathway | Metabolic & Weight Loss |
| Research Phase | Research Only |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-15